Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.
|Articles|March 1, 1999
The American Journal of Managed Care
- March 1999
- Volume 5
- Issue 3
Correspondence regarding, "Insurance Type and the Transportation to Emergency Departments of Patients With Acute Cardiac Ischemia"
Advertisement
Articles in this issue
over 27 years ago
Economic Impact of Delaying or Preventing AIDS in Persons with HIVover 27 years ago
Erectile Dysfunction: The Primary Care Practitioner's Viewover 27 years ago
Drug-Nutrient InteractionsAdvertisement
Related to this article
Most community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Switching MS patients to subcutaneous ocrelizumab cut chair time 82.8% and delivered $514,544 in 3-year value, a UVA analysis finds.
Topical ruxolitinib prescribing in Medicare Part D surged through 2024, but its cost per day runs 16 times higher than generic tacrolimus.
Baseline biopsies separated 16 patients who later developed hepatocellular carcinoma from 32 matched controls a median 6.1 years ahead.
A narrative review finds specialty pharmacies lack a patient-reported outcome measure built for their workflow, despite frequent contact with patients with MS.
Patients with colorectal or ovarian cancer enrolled in a clinical trial have lower pharmacy and medical costs during the 9 months after trial initiation.
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Nearly a Decade After CAR T, Medicare’s Cell and Gene Therapy Payment Gap Persists
3
Twice-Daily Deuruxolitinib Outperformes Once-Daily in Severe AA
4
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
5